ImmunoGen (NASDAQ:IMGN) Analyst Rating Consensus

ImmunoGen (NASDAQ:IMGN) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.48 by 9 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 5 Brokerage Firms have advised hold. 1 Analysts have rated it as strong sell.

Other Equity analysts have also commented on the company shares. Brokerage firm RBC Capital downgrades its rating on ImmunoGen (NASDAQ:IMGN). The shares have been rated Sector Perform. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on May 2, 2016.

ImmunoGen (NASDAQ:IMGN): The mean estimate for the short term price target for ImmunoGen (NASDAQ:IMGN) stands at $11.19 according to 8 Analysts. The higher price target estimate for the stock has been calculated at $24 while the lower price target estimate is at $5.

ImmunoGen (NASDAQ:IMGN) witnessed a decline in the market cap on Tuesday as its shares dropped 3.57% or 0.12 points. After the session commenced at $3.37, the stock reached the higher end at $3.4499 while it hit a low of $3.19. With the volume soaring to 1,491,682 shares, the last trade was called at $3.24. The company has a 52-week high of $19.43. The company has a market cap of $282 million and there are 87,076,978 shares in outstanding. The 52-week low of the share price is $3.19.

ImmunoGen, Inc. has lost 7.16% in the last five trading days and dropped 41.83% in the last 4 weeks. ImmunoGen, Inc. has dropped 61.88% during the last 3-month period . Year-to-Date the stock performance stands at -76.12%.

ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Companys clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Companys partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Companys collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Companys compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *